Drug Trial Radar · NCT02207816
An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa
Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,084
Actual
Start
Sep 18, 2014
Primary completion
Jan 31, 2017
Study completion Jan 31, 2017
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 4, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 42 months, up to 9 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following a primary vaccination series (NCT00866619). No new subjects will be enrolled in this extension study.
Conditions
- Malaria
Interventions
Blood samplingProcedure
Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
Malaria Vaccine 257049 (MALARIA-055 PRI)Biological
Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)Biological
Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
Cell-culture rabies vaccine (MALARIA-055 PRI)Biological
Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
TritanrixHepB/Hib (MALARIA-055 PRI)Biological
Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)Biological
Administered orally, during the MALARIA-055 study (NCT00866619).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Severe Malaria Meeting Case Definition 1Time frame: From Year 0 to Year 3 (Starting January 2014 and ending December 2016)
- Incidence of Severe Malaria Meeting Case Definition 2.Time frame: From Year 0 to Year 3 (Starting January 2014 and ending December 2016)
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Ouagadougou, Burkina Faso
GSK Investigational Site
Kisumu, Kenya
GSK Investigational Site
Tanga, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.